Core Viewpoint - NRx Pharmaceuticals has appointed Prof. Joshua C. Brown as Chief Medical Innovation Officer to enhance its drug development program focused on treating PTSD and depression in military personnel, veterans, and first responders [1][5]. Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [7]. - The company is working on NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression [7]. Appointment of Prof. Joshua C. Brown - Prof. Brown is a psychiatrist, neurologist, and neuroscientist with significant expertise in Transcranial Magnetic Stimulation (TMS) and neuroplastic medications [2][3]. - He has over $20 million in federal funding for TMS research and holds a position at Harvard Medical School [2]. - His role at NRx will involve collaboration with Dr. Dennis McBride to advance TMS as a therapy for combat-related depression and PTSD [3]. Research and Development Focus - NRx has filed an Investigational New Drug application with the FDA to test a combination therapy involving ketamine, TMS, and NRX-101 in its HOPE Therapeutics clinic network [4]. - Recent evidence indicates a high return-to-duty rate among first responders with PTSD treated with ketamine, TMS, and hyperbaric oxygen [4]. Strategic Vision - Prof. Brown emphasizes the importance of academic-industry partnerships to bridge the gap between scientific discovery and real-world application, particularly in addressing the rising burden of depression, anxiety, PTSD, and suicide [6]. - NRx is committed to translating TMS-pharmacologic augmentation strategies into effective treatments for patients suffering from serious brain disorders [6].

Core Insights - Neuronetics Inc. shares increased by 41.08% to $2.06 in after-hours trading following preliminary fourth-quarter 2025 financial results [1] Financial Performance - The company reported fourth-quarter 2025 revenue of $41.8 million, representing a 23% increase on an adjusted pro forma basis and an 86% increase compared to fourth-quarter 2024 on an as-reported basis [2] - Revenue from the NeuroStar system was $18.3 million, up 9% pro forma, while clinic revenue reached $23.5 million, up 37% pro forma [2] - Full-year 2025 revenue totaled $149.2 million, up 15% on an adjusted pro forma basis [4] - Neuronetics ended 2025 with $34.1 million in total cash, including cash equivalents and restricted cash [4] Operational Highlights - The company shipped 49 NeuroStar Advanced Therapy systems and generated positive operating cash flow of $0.9 million during the quarter, consistent with previously issued guidance [3] - CEO Keith Sullivan emphasized the translation of strong revenue performance into positive operating cash flow during the quarter [4] Market Metrics - Neuronetics has a market capitalization of $99.99 million, with a 52-week high of $5.91 and a 52-week low of $1.25 [5] - The stock has declined by 62.85% over the past 12 months, closing at $1.46, down 2.01% [5]

Core Insights - Neuronetics, Inc. has announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, marking a significant advancement in treatment accessibility for this demographic [1][2][3] Company Overview - Neuronetics, Inc. specializes in medical technology aimed at improving the quality of life for patients with neurohealth disorders, particularly through its NeuroStar Advanced Therapy [1][5] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for treating major depressive disorder (MDD) and other mental health conditions across the United States [5] Industry Context - TRICARE coverage is primarily utilized by active and retired military personnel and their families, with the new policy affecting beneficiaries in 26 states [2] - An estimated 4.3 million U.S. adolescents aged 15-21 are affected by major depression, highlighting the need for effective treatment options [3] - NeuroStar TMS therapy is recognized as a safe and effective first-line treatment for adolescents with major depressive disorder, especially given the limited medication options available [3][6] Treatment Efficacy - NeuroStar Advanced Therapy has delivered over 7.9 million treatments and is supported by the largest clinical data set for TMS treatment of depression [5] - The therapy is FDA-cleared for various indications, including as a first-line adjunct treatment for adolescents aged 15-21 with MDD [6]

Core Insights - HOPE Therapeutics has initiated patient care for treatment-resistant depression using the Ampa One Day (ONE-D) protocol, marking a significant advancement in TMS therapy [1][2] - The Ampa device has shown promising results with an 87% response rate and a 72% remission rate in nonrandomized trials when combined with D-cycloserine and lisdexamfetamine [1][5] - The ONE-D protocol reduces the treatment duration from 90 days to a single day, offering a new paradigm for patients suffering from severe depression [2][3] Company Overview - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is focused on building a network of interventional psychiatry clinics that provide various therapies, including TMS and neuroplastic medications [4] - The company is expanding its presence in Florida, with plans to operate six clinic locations by the end of 2025 [2][5] - Dr. Rebecca Cohen, the Medical Director of HOPE, is the first Ampa-certified psychiatrist in Florida, leading the deployment of the Ampa device [5] Treatment Protocol - The ONE-D protocol combines TMS with physician-prescribed D-cycloserine and lisdexamfetamine, aiming to achieve remission from treatment-resistant depression [4][5] - D-cycloserine has been shown to enhance the effectiveness of TMS significantly, with studies indicating a more than two-fold increase in treatment efficacy [1][3] Research and Development - NRx Pharmaceuticals is developing NRX-100 and NRX-101, targeting central nervous system disorders, including suicidal depression and PTSD [5][6] - NRX-101 has received Breakthrough Therapy designation for treating suicidal bipolar depression, highlighting the company's commitment to addressing critical mental health issues [6]

Company Overview - The company combines mental health services and device expertise to treat more patients[17] - The company has treated 229,429 unique patients and administered 8,213,816 treatments[18, 19] - The company reported $129 million in annual revenue for 2024[19] Market and Clinical Data - The total available market consists of 293 million individuals affected by depression and OCD[34] - Approximately 8 million patients are poorly served by antidepressant medication[35] - 83% of patients experienced improvement in depression symptoms, and 62% achieved symptom relief (remission)[47] Financial Performance and Guidance - Q3 2025 revenue reached $373 million, a 101% increase compared to Q3 2024[92] - The company projects FY 2025 revenue between $147 million and $150 million, representing a 14% to 16% adjusted pro forma year-over-year growth[87] - The company is targeting positive cash flow from operations in Q4 2025[87] Growth Initiatives - The company is expanding the Better Me Provider (BMP) network, with over 420 BMP clinics in 49 states[23] - The company is expanding SPRAVATO® treatment to 89 treatment centers by the end of Fiscal Year 2025[76] - NeuroStar University (NSU) attendees have started 38% more patients, and performed 26% more treatment sessions YTD than non-attendees[65, 69]

Core Points - New York State Medicaid will cover Transcranial Magnetic Stimulation (TMS) services for adults diagnosed with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members and November 1, 2025, for those in Managed Care Plans [1][2] - This policy change will benefit nearly 1 million individuals with fee-for-service Medicaid and over 4.4 million individuals with Managed Care Organizations in New York [2] - Major depressive disorder affects 21 million adults in the U.S., with 6.4 million unable to tolerate or receiving inadequate relief from antidepressants [3] Company Overview - Neuronetics, Inc. is a medical technology company focused on neurohealth disorders and is the maker of NeuroStar Advanced Therapy, the leading provider of TMS [1][5] - NeuroStar Advanced Therapy is a non-drug, non-invasive treatment that has shown an 83% response rate and a 62% remission rate for MDD patients [3] - Neuronetics operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Advanced Therapy and has delivered over 7.6 million treatments [5] Industry Context - The decision by New York State Medicaid reflects a growing recognition of TMS as an evidence-based treatment for depression [2] - Neuronetics is the only TMS company with a dedicated health policy team advocating for health policy updates [4] - The NeuroStar Advanced Therapy System is FDA-cleared for various indications, including MDD and anxiety symptoms in adults [6]

Company Overview - Neuronetics and Greenbrook have combined to leverage scale and capabilities for mental health treatment[17] - The combined company has treated 221,376 unique patients[18] and administered 7,912,427 treatments[19] - The company reported $129 million in annual revenue for 2024 (pro forma adjusted)[19] Market and Opportunity - The total available market is 293 million U S adults and adolescents suffering from depression, depression with anxiety, and OCD[33,34] - Approximately 8 million patients are poorly served by antidepressant medication[34] - Better Me Program (BMP) clinics treat 33 times more patients than non-BMP clinics[57,58] Financial Performance and Guidance - Q2 2025 revenue was $381 million, a 132% increase from Q2 2024[90] - The company projects revenue between $149 million and $155 million for FY 2025, representing a 15% to 19% pro forma year-over-year growth[85] - The company anticipates achieving positive cash flow from operations in Q4 2025[85]

Core Insights - Neuronetics, Inc. reported total revenue of $38.1 million for the second quarter of 2025, reflecting an 18% adjusted pro forma revenue growth and a 132% increase compared to the same quarter in 2024 [1][6][5] - The company achieved record revenue of $23.0 million from Greenbrook clinics during the quarter, contributing significantly to the overall revenue growth [1][6] - Cash used in operations was reduced to $3.5 million, outperforming the guidance of under $5 million [1][4] Financial Performance - Total revenues for the three months ended June 30, 2025, were $38.1 million, up from $16.5 million in the same period of 2024, primarily due to the acquisition of Greenbrook [5][6] - U.S. clinic revenue was $23.0 million, while international revenue increased by 41% to $452,000 [5][7] - Gross margin decreased to 46.6% from 74.0% year-over-year, mainly due to the inclusion of Greenbrook's clinic business [10] Operational Highlights - The company shipped 41 NeuroStar Advanced Therapy Systems, generating $3.5 million in revenue, although this represented a 13% decrease compared to the previous year [8][6] - U.S. treatment session revenue was $10.8 million, an 8% decrease year-over-year, but a 13% increase on a pro forma basis [9][6] - Neuronetics treated over 209,000 global patients with 7.6 million treatment sessions [6] Management and Strategic Developments - Steven Pfanstiel was appointed as the new Chief Financial Officer, bringing over 20 years of healthcare experience [16] - The company secured an additional $10 million in funding from Perceptive Advisors LLC, extending its liquidity requirements [14] - Neuronetics expects total worldwide revenue for the third quarter of 2025 to be between $37.0 million and $39.0 million, and for the full year 2025, between $149.0 million and $155.0 million [17][18] Future Outlook - The company anticipates gross margin improvement in the second half of 2025, expecting it to be between 48% and 50% [18] - Total operating expenses for 2025 are now projected to be between $100.0 million and $105.0 million, reflecting the integration of Greenbrook [19] - Neuronetics expects to achieve positive cash flow from operations in the fourth quarter of 2025 [20]

Core Insights - Neuronetics, Inc. has published significant findings demonstrating the effectiveness of NeuroStar TMS in treating adolescents and young adults with depression, as reported in a leading medical journal [1][2] Company Overview - Neuronetics is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative products [4] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for major depressive disorder (MDD) and other mental health conditions across the United States [4] Treatment Efficacy - The study based on the NeuroStar TrakStar Clinical Database involved 1,283 patients, with approximately 70% reporting clinically meaningful improvement in depression symptoms, while less than 1% experienced worsening [2][3] - The results for adolescents and young adults align with previous findings in adult populations, indicating a strong correlation between the number of treatment sessions completed and clinical improvement [2] Market Opportunity - With one in five adolescents experiencing major depressive disorder and limited FDA-approved medications available, NeuroStar TMS presents a significant opportunity to provide a safe and effective treatment option for this demographic [3] - Since receiving FDA clearance as an add-on therapy for adolescents aged 15-21 in March 2024, there has been over a one-third increase in the number of adolescents treated with NeuroStar [2]

Core Insights - NeuroStar, a Silver Sponsor at the 13th Annual Clinical TMS Society (CTMSS) Meeting, is committed to clinical innovation and excellence in mental health care [1][2] - The company will present two significant poster presentations based on the TrakStar data set, which is the largest real-world outcomes database in TMS [2][3] - NeuroStar aims to optimize TMS efficacy and expand its use into new populations and protocols, reinforcing its leadership in the psychiatric community [3] Company Updates - NeuroStar will present a retrospective analysis comparing clinical outcomes between its proprietary Figure-8 coil and Brainsway's H-coil in treating depression [2] - The company is evaluating personalized qEEG-informed protocols for TMS therapy, demonstrating operational feasibility with the NeuroStar TMS System [4] - NeuroStar has delivered over 7.4 million treatments and operates Greenbrook TMS centers across the U.S. for treating Major Depressive Disorder (MDD) and other mental health disorders [6] Event Participation - The CTMSS Meeting will take place from June 11-14 in San Diego, CA, where NeuroStar will also participate in the PULSES Course for TMS providers [2] - Presentations will include data on elderly adults (age 70 and older) with MDD treated with TMS, and a retrospective analysis from 200 Greenbrook centers [7]